GC-MS procedure for the analysis of zipeprol.
A sensitive and specific quantitative method for the determination of zipeprol, a newly abused antitussive, in human fluids is described. Zipeprol and an internal standard, levallorphan, are isolated by a basic extraction and back-extraction process. The final extract is derivatizated with BSTFA + 1% TMCS and separated on a 12-m HP-1 capillary column. Drugs are detected by selected ion monitoring at m/z 335 and m/z 355 for zipeprol and the internal standard, respectively. The minimum detectable quantities are 0.6 and 0.4 ng ml-1, for zipeprol in plasma and urine, respectively. Relative standard deviations for within-run data are less than 6%.
Kintz
P
P
Institut de Médecine Légale, Strasbourg, France.
Flesch
F
F
Jaeger
A
A
Mangin
P
P
D000328:Adult; D000996:Antitussive Agents / Q000032:analysis* / Q000097:blood / Q000506:poisoning; D008401:Gas Chromatography-Mass Spectrometry; D005766:Gastrointestinal Contents / Q000737:chemistry; D006801:Humans; D007202:Indicators and Reagents; D007977:Levallorphan / Q000032:analysis; D008297:Male; D010879:Piperazines / Q000032:analysis* / Q000097:blood / Q000506:poisoning; D012997:Solvents; D013406:Suicide, Attempted
D000996:Antitussive Agents; D007202:Indicators and Reagents; D010879:Piperazines; D012997:Solvents; D007977:Levallorphan; C013341:zipeprol